Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada

類似資料

• Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
  著者:: Gerth, William C, 等
  出版事項: (2014)
• Protein-glycan interactions as targets of intravenous/subcutaneous immunoglobulin (IVIg/SCIg) preparations
  著者:: von Gunten, S
  出版事項: (2014)
• Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)
  著者:: Gill, Parwinder K., 等
  出版事項: (2018)
• Streptococcus pneumoniae antibody titres in patients with primary antibody deficiency receiving intravenous immunoglobulin (IVIG) compared to subcutaneous immunoglobulin (SCIG)
  著者:: Knutsen, A P, 等
  出版事項: (2015)
• Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
  著者:: Scheuerlein, Philipp, 等
  出版事項: (2018)